China's Proposed API Priority Review Policy: China's Localisation Strategy Expands into APIs

On 2 June 2026, China's National Medical Products Administration (NMPA) released a draft proposal for public consultation that would grant priority review status to certain active pharmaceutical ingredients (APIs).

The draft proposal outlines three circumstances under which an API may qualify for priority review:

1. APIs used in urgently needed medicines included on China's drug shortage lists, or otherwise deemed critical to public health.

2. The first domestic registration of an API developed as a local alternative to an imported API currently used in a marketed drug product in China.

3. Overseas-manufactured APIs used in originator products seeking registration in China.

While the proposal is presented as a regulatory measure, it may also signal a broader policy objective. In particular, the second category provides a clear incentive for the development and registration of domestic alternatives to APIs currently sourced from overseas suppliers.

This proposal should be viewed alongside a range of other industrial and healthcare policies aimed at strengthening China's domestic pharmaceutical manufacturing capabilities. If implemented, such measures may gradually erode the market share of imported APIs in China and, over time, strengthen the global competitiveness of Chinese API manufacturers.

Innovative and specialised API companies should closely monitor the development of this policy and assess its potential implications for their China strategy, global market positioning, and long-term competitive landscape.

There is only so much that individual companies can do in response to a policy direction supported by a strong national industrial strategy. The proposal may therefore also warrant attention from industry associations, policymakers, and regulators in Western markets concerned about the resilience and competitiveness of their own pharmaceutical supply chains.

At MAAB, we help international pharmaceutical companies look beyond the regulations themselves and understand the commercial implications behind policy changes. With experience spanning both multinational pharmaceutical companies and the Chinese healthcare market, we aim to serve as a trusted partner for organizations seeking to navigate China's evolving life sciences landscape and build successful long-term collaborations.

Source: https://www.nmpa.gov.cn/xxgk/zhqyj/zhqyjyp/20260602164431134.html

Keywords:

China API

China pharmaceutical policy

China drug regulation

China market access